Teacher Retirement System of Texas Sells 11,886 Shares of Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas lowered its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 11.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,496 shares of the company's stock after selling 11,886 shares during the quarter. Teacher Retirement System of Texas' holdings in Moderna were worth $2,537,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vontobel Holding Ltd. increased its stake in shares of Moderna by 1.3% in the first quarter. Vontobel Holding Ltd. now owns 261,706 shares of the company's stock valued at $7,419,000 after buying an additional 3,338 shares during the period. Mather Group LLC. grew its holdings in Moderna by 472.1% during the 1st quarter. Mather Group LLC. now owns 3,879 shares of the company's stock worth $110,000 after acquiring an additional 3,201 shares during the last quarter. Deseret Mutual Benefit Administrators increased its position in Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after acquiring an additional 392 shares during the period. KBC Group NV raised its stake in shares of Moderna by 2.4% during the first quarter. KBC Group NV now owns 44,461 shares of the company's stock valued at $1,261,000 after acquiring an additional 1,058 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Moderna by 13.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,028 shares of the company's stock worth $1,619,000 after purchasing an additional 6,207 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MRNA shares. Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Morgan Stanley lowered their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Royal Bank Of Canada reduced their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a report on Thursday, May 22nd. Finally, Barclays lowered their target price on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $46.61.

Moderna Stock Up 4.5%

NASDAQ:MRNA traded up $1.49 on Thursday, hitting $34.28. The stock had a trading volume of 11,679,141 shares, compared to its average volume of 8,823,154. The company has a market cap of $13.26 billion, a PE ratio of -3.93 and a beta of 1.84. The business's fifty day moving average is $26.95 and its 200 day moving average is $31.30. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The firm had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. During the same period last year, the company earned ($3.07) earnings per share. The business's revenue was down 35.3% on a year-over-year basis. Equities analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.